Investigación Programas
Investigación

CoViproteHCt

Imagen 3D coronavirus
Foto: Freepik user2109397
Duración
18/4/2020 - 31/12/2021
Coordinador
Technische Universität München
Financiadores
EIT Health

The current restrictions related to SARS-CoV-2 impose a major burden on our healthcare system, society and economy. A significant gap is the lack of test systems to identify people already immune to SARS-CoV-2 and who would thus be protected from re-infection. While development of numerous serological assays is underway worldwide, it remains unknown whether the measured immune responses are truly protective. CoViproteHCt addresses this gap by rapidly developing and validating such urgently needed assays to characterize protective immune responses that can then be used to identify protected individuals, in particular healthcare personnel (HCP) working with COVID-19 patients and in other critical areas. The developed assays can subsequently be adapted by companies and academic partners throughout the world within weeks.
This approach will allow the selective release of HCP from quarantine restrictions and their subsequent return to work, thus stabilizing our healthcare system and economy.

Funding

678.671 €

Nuestro equipo

Equipo ISGlobal

Otros proyectos

Ver proyectos pasados

COMBACTE

Combatiendo la Resistencia Bacteriana en Europa

COMBACTE-CARE

Combatting Bacterial Resistance in Europe - Carbapenem Resistance

Xpatial-TB

Improved case detection through TB contact risk stratification by Xpert results and spatial parameters in Mozambique

WHIP3TB

Evaluation of the effect of weekly high dose rifapentine and isoniazid (3HP) vs periodic 3HP vs 6H for preventing TB among HIV-positive individuals

VINCI

Optimizing provider-initiated HIV testing, linkage, and retention in care in the district of Manhiça, Mozambique

INTE-AFRICA

Integrating and decentralizing diabetes and hypertension services in Africa

AVATAR

Searching the hidden: evaluating dengue, chikungunya and Zika autochthonous transmission in the city of Barcelona.

COVID-PREG

Eficacia de hidroxicloroquina en la prevención de la infección por SARS-CoV-2 y de la gravedad de la enfermedad de COVID-19 durante el embarazo

AMR DetecTool

A breakthrough device for the rapid detection of antimicrobial resistance

ANTICOV

Large Clinical Trial in Africa on the Treatment of Mild Cases of COVID-19

HBV-COMSAVA

Hepatitis B Virus COMmunity Screening and Vaccination in Africans

Stool4TB

Evaluating a new stool based qPCR for diagnosis of tuberculosis in children and people living with HIV

Hep C Free Baleares

Eliminating hepatitis C on the Balearic Islands (Mallorca, Menorca and Ibiza): a study in governmental and non-governmental addiction service centres, a mobile methadone unit and a prison to test and link people who use drugs to HCV care.

CAPTB

Close the Gap, Increase Access, Provide Adequate Therapy

STREESCO

Strengthening Epidemiological Surveillance in Benin and Burkina Faso for an Effective Response to COVID-19

COVAIR-CAT

Air Pollution in Relation to COVID-19 Morbidity and Mortality: A Large Population-Based Cohort Study in Catalonia

TB-RECONNECT

Reconnecting Transmission to Global Tuberculosis Control by Mapping Pathogen Transmission Events to Host Infection Status

SToolNIH

Quantifiable stool-based TB PCR to Improve Diagnostics and Treatment Monitoring

END-VOC

ENDing COVID-19 Variants Of concern through Cohort studies (END-VOC)